Last reviewed · How we verify
MBI 226 Acne Solutions
At a glance
| Generic name | MBI 226 Acne Solutions |
|---|---|
| Sponsor | BioWest Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne (PHASE2)
- Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MBI 226 Acne Solutions CI brief — competitive landscape report
- MBI 226 Acne Solutions updates RSS · CI watch RSS
- BioWest Therapeutics Inc portfolio CI